Foghorn Therapeutics Inc.
FHTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $23 | $34 | $19 | $1 |
| % Growth | -33.8% | 77.6% | 1,357.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $23 | $34 | $19 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $95 | $110 | $106 | $80 |
| G&A Expenses | $28 | $32 | $31 | $22 |
| SG&A Expenses | $28 | $32 | $31 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Expenses | $125 | $142 | $136 | $102 |
| Operating Income | -$103 | -$108 | -$117 | -$101 |
| % Margin | -454.3% | -315.9% | -609.2% | -7,637.1% |
| Other Income/Exp. Net | $16 | $14 | $8 | -$1 |
| Pre-Tax Income | -$87 | -$94 | -$109 | -$101 |
| Tax Expense | $0 | $4 | $0 | $0 |
| Net Income | -$87 | -$98 | -$109 | -$101 |
| % Margin | -383.2% | -288.2% | -566.3% | -7,681.6% |
| EPS | -1.58 | -2.34 | -2.62 | -2.78 |
| % Growth | 32.5% | 10.7% | 5.8% | – |
| EPS Diluted | -1.58 | -2.34 | -2.62 | -2.78 |
| Weighted Avg Shares Out | 55 | 42 | 42 | 37 |
| Weighted Avg Shares Out Dil | 55 | 42 | 42 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $11 | $6 | $0 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $3 | $3 | $3 | $3 |
| EBITDA | -$97 | -$104 | -$114 | -$96 |
| % Margin | -429.9% | -305.8% | -591.9% | -7,292.4% |